Track Senti Biosciences Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Senti Biosciences Inc. Common Stock SNTI · Stock Open Senti Biosciences Inc. Common Stock in new tab

0.1400 USD
P/E
4.54
EPS
-1.72
P/B
-1.46
ROE
-466.46
Beta
2.32
Target Price
13.50 USD
Loading chart...
Key Metrics
Earnings dateMarch 26, 2027
P/E4.54
EPS-1.72
Book Value-0.11
Price to Book-1.46
Debt/Equity746.24
% Insiders47.865%
Estimates
Forward P/E-0.17
Forward EPS-0.95
Target Mean Price13.50

DCF valuation

Model fair value for Senti Biosciences Inc. Common Stock (SNTI)
Result
Sign in to run the valuation for SNTI.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
2 analysts · consensus None · mean target 13.50 USD (low 12.00, high 15.00) · as of 10 Nov 2026
Low 12.00
Mean 13.50
High 15.00
Price 0.1400
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Senti Biosciences Inc. Common Stock Logo Senti Biosciences Inc. Common Stock Analysis (SNTI)

United States Health Care Official Website Stock

Is Senti Biosciences Inc. Common Stock a good investment? Senti Biosciences Inc. Common Stock (SNTI) is currently trading at 0.1400 USD. Market analysts have a consensus price target of 13.50 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 4.54. This relatively low multiple may signal that Senti Biosciences Inc. Common Stock is undervalued compared to historical market norms.

Earnings Schedule: Senti Biosciences Inc. Common Stock is expected to release its next earnings report on March 26, 2027. The market consensus estimate for Forward EPS is -0.95.

Investor FAQ

Does Senti Biosciences Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Senti Biosciences Inc. Common Stock?

Senti Biosciences Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 26, 2027. The company currently has a trailing EPS of -1.72.

Company Profile

Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia. In addition, the company develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd. The company was formerly known as Senti Biosciences, Inc. and changed its name to Senti Biosciences Holdings, Inc. in April 2026. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Exchange Ticker
NMS (United States) SNTI
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
July 18, 2024 1:10
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion